Novel inhibitors of HIV integrase: The discovery of potential anti-HIV therapeutic agents

Current Pharmaceutical Design

Volumn 9, Issue 31, 2003, Pages 2553-2565

  Nair, Vasu ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 3' AZIDO 3' DEOXYTHYMIDINE DIPHOSPHATE; 3' AZIDO 3' DEOXYTHYMIDINE MONOPHOSPHATE; 3' AZIDO 3' DEOXYTHYMIDINE TRIPHOSPHATE; AMINOACRIDINE; ANTIRETROVIRUS AGENT; CAMPTOTHECIN; CHLOROQUINE; DIHYDROXYNAPHTHOQUINONE; DINUCLEOTIDE; DINUCLEOTIDE 5' PHOSPHATE; DOXORUBICIN; ELLIPTICINE; ETHIDIUM BROMIDE; HETEROCYCLIC COMPOUND; INTEGRASE; INTEGRASE INHIBITOR; INTERCALATING AGENT; MITOXANTRONE; NATURAL PRODUCT; NUCLEOTIDE; NUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE; OXOACID; PRIMAQUINE; SULFONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA; VIRUS ENZYME; ZIDOVUDINE;

CHROMOSOME; DNA INTEGRATION; DNA SEQUENCE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GENOME; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; REVIEW; STRUCTURAL GENE; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; DRUG DESIGN; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NUCLEOTIDES; OLIGONUCLEOTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS INTEGRATION;

EID: 0344276472     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033453703     Document Type: Review

References (57)

1. Vaishnav YN, Wong-Staal F. The biochemistry of AIDS. Annu Rev Biochem 1991; 60: 577-630.
2. Fauci AS. Multifactorial nature of human immunodeficiency viral disease: Implications for therapy. Science 1993; 262: 1011-1018.
3. Luciw PA. In "Fundamental Virology," Lippincott-Raven: Philadelphia PA, 1996; pp. 845-916.
4. Fauci AS. The human immunodeficiency virus: Infectivity and mechanisms of Pathogenesis. Science 1988; 239: 617-622.
5. Levy JA. "HIV and the Pathogenesis of AIDS," ASM Press: Washington DC, 1994.
6. De Clercq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem 1995; 38: 2491-2517.
7. De Clercq E. Antiviral therapy of human immunodeficiency virus infections. Clin Microbiol Rev 1995; 8: 200-239.
8. Katz RA, Skalka AM. The retroviral enzymes. Annu Rev Biochem 1994; 63: 133-173.
9. Johnson SC, Gerber JG. Advances in HIV/AIDS therapy. In "Advances in Internal Medicine," Volume 44. Schrier RW, Baxter JD, Dzau VJ, Fauci AS, eds. Mosby: St. Louis 2000; pp. 1-40.
10. DeClercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997; 10: 674-693.
11. Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res 1999; 52: 351-369.
12. Esposito D, Craigie R. HIV integrase structure and function. Adv Virus Res 1999; 52: 319-333.
13. Greenwald J, Le V, Butler SL, Bushman FD, Choe S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 1999; 38: 8892-8898.
14. Haren L, Ton-Hoang B, Chandler M. Integrating DNA: transposases and retroviral integrases. Annu Rev Microbiol 1999; 53: 245-281.
15. Lutzke RAP, Vink C, Plasterk RHA. Characterization of the minimal DNA- binding domain of the HIV integrase protein. Nucleic Acids Res 1994; 22: 4125-4131.
16. Hazuda DJ, Wolfe AL, Hastings JC, Robbins HL, Graham PL, LaFemina RL, et al. Viral long terminal repeat substrate binding characteristics of HIV-1 Integrase. J Biol Chem 1994; 269: 3999-4004.
17. Jenkins TM, Hickman AB, Dyda F, Ghirlando R, Davies DR, Craigie R. Catalytic domain of HIV-1 integrase: Identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc Natl Acad Sci USA 1995; 92: 6057-6061.
18. Leavitt AD, Shiue L, Varmus HE. Site-directed mutagenesis of HIV-1 integrase demonstrates differential effects on integrase functions in vitro. J Biol Chem 1993; 268: 2113-2119.
19. Burke CJ, Sanyal G, Bruner MW, Ryan JA, LaFemina RL, Robbin HL, et al. Structural implication of spectroscopic characterization of putative zinc finger peptide from HIV-1 integrase. J Biol Chem 1992; 267: 9639-9644.
20. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266: 1981-1986.
21. Mazumder A, Gazit A, Levitzki A, Nicklaus M, Yung J, Kohlhagen G, et al. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type I integrase. Biochemistry 1995; 34: 15111-15122.
22. Mazumder A, Cooney D, Agbaria R, Gupta M, Pommier Y. Inhibition of human immunodeficiency virus type 1 integrase by 3′-azido-3′-deoxythymidylate. Proc Natl Acad Sci USA 1994; 91: 5771-5775.
23. Mazumder A, Neamati N, Sommadossi J-P, Gosselin G, Schinazi RF, Imbach J-L, et al. Effect of nucleotide analogues on human immunodeficiency virus type 1 integrase. Mol Pharmacol 1996; 49: 621-628.
24. Nair V, Nuesca ZM. Isodideoxynucleosides: A conceptually new class of nucleoside antiviral agents. J Am Chem Soc 1992; 114: 7951-7953.
25. Nair V, Jahnke TS. Antiviral activity of isomeric dideoxynucleosides of D- and L- related stereochemistry. Antimicrob Agents Chemother 1995; 39: 1017-1029.
26. Nair V, St. Clair M, Reardon JE, Krasny HC, Hazen RJ, Paff MT, et al. Antiviral, metabolic and pharmacokinetic studies on the isomeric dideoxynucleoside, 4(S)-(6-amino-9H-purin-9-tetrahydro-2(S)- furanmethanol. Antimicrob Agents Chemother 1995; 39: 1993-1999.
27. Zhang J, Neamati N, Pommier Y, Nair V. Inhibition of HIV integrase by novel nucleotides bearing tricyclic bases. Bioorg Med Chem Lett 1998; 8: 1887-1890.
28. Ojwang JO, Buckheit RW, Pommier Y, Mazumder A, De Vreese K, Este JA, et al. T30177, An oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type I. Antimicrob Agents Chemother 1995; 39: 2426-2435.
29. Mouscadet J-F, Carteau S, Goulaouic H, Subra F, Auclair C. Triplex-mediated inhibition of HIV DNA integration in vitro. J Biol Chem 1994; 269: 21625-21638.
30. Mouscadet J-F, Ketterle C, Carteau S, Goulaouic H, Subra F, Le Bret M, et al. Triplex helix formation with short oligonucleotide-intercalator conjugates matching the HIV-1 U3 LTR end sequence. Biochemistry 1994; 33: 4187-4196.
31. Mazumder A, Neamati N, Ojwang JO, Sunder S, Rando RF, Pommier Y. Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 1996; 35: 13762-13771.
32. Mazumder A, Uchida H, Neamati N, Sunder S, Jaworska-Maslanka M, Wickstrom E, et al. Probing interactions between viral DNA and human immunodeficiency virus type 1 integrase using dinucleotides. Mol Pharmacol 1997; 51: 567-575.
33. Taktakishvili M, Neamati N, Pommier Y, Pal S, Nair V. Recognition and inhibition of HIV integrase by novel dinucleotides. J Am Chem Soc 2000; 122: 5671-5677.
34. Taktakishvili M, Neamati N, Pommier Y, Nair V. Recognition and inhibition of HIV-1 integrase by a novel dinucleotide. Bioorg Med Chem Lett 2000; 10: 249-251.
35. Taktakishvili M, Neamati N, Pommier Y, Nair V. Discovery of a nuclease-resistant, non-natural dinucleotide that inhibits HIV Integrase. Bioorg Med Chem Lett 2001; 11: 1433-1435.
36. Nair V, Taktakishvili M, Neamati N, Pommier Y. Recognition and inhibition of HIV integrase by novel dinucleotides. Antiviral Res 2000; 46: A44.
37. Mazumder A, Neamati N, Sundar S, Owen J, Pommier Y. In Methods in Cellular and Molecular Biology: Antiviral Evaluation; Kinchington D, Schinazi R, Eds, Humana: Totowa, 1998.
38. Jahnke TS, Nair V. 2′-Deoxyadenylyl-(3′→5′)-isodideoxyadenosine. A unique dinucleotide: synthesis and characterization. Bioorg Med Chem Lett 1995; 5: 2235-2238.
39. Wenzel T, Nair V. Novel oligodeoxyribonucleotides incorporating L-related isodeoxynucleosides: Solid phase synthesis, enzymology, and CD studies. Bioorg Med Chem Lett 1997; 7: 3195-3198.
40. Wenzel T, Nair V. Self-complimentary oligodeoxyribonucleotides incorporating L-related isodideoxynucleosides: Synthesis, physical characterization, enzymology, and CD studies. Bioconjugate Chemistry 1998; 9: 683-690.
41. Taktakishvili M, Nair V. A new method for the phosphorylation of nucleosides. Tetrahedron Lett. 2000; 41: 7173-7176.
42. Ellison V, Brown PO. A stable complex between integrase and viral DNA ends mediates human immunodeficiency virus integration in vitro. Proc Natl Acad Sci USA 1994; 91: 7316-7320.
43. Marshall WS, Caruthers MH. Phosphorodithioate DNA as a potential therapeutic drug. Science 1993; 259: 1564-1570.
44. Torrence PF, Imai J, Johnston MI. Assay of 2,′5′-oligoadenylate phosphodiesterase activity in mouse L-cell extracts. Anal Biochem 1993; 129: 103-110.
45. Sokolova NI, Dolinnaya NG, Krynetskaya NF, Shabarova ZA. Dinucleoside phosphates containing arabinose or deoxyxylose. Hydrolysis by exonuclease and stacking properties. Nucleosides & Nucleotides 1990; 9: 515-531.
46. Fesen MR, Kohn KW, Leteurtre F, Pommier Y. Inhibitors of human immunodefiency virus integrase. Proc Natl Acad Sci USA 1993; 90: 2399-2403.
47. Mathe C, Nair V. Potential inhibitors of HIV integrase. Nucleosides & Nucleotides 1999; 18: 681-682.
48. LaFemina RL, Graham PL, LeGrow K, Hastings JC, Wolfe A, Young SD, et al. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob.Agents Chemother. 1995; 39: 320-324.
49. Burke Jr TR, Fesen MR, Mazumder A, Wang J, Carothers A, Grunberger D, et al. Hydroxylated aromatic inhibitors of HIV-1 Integrase. J Med Chem 1995; 38: 4171-4178.
50. Puras Lutze RA, Eppens NA, Weber P, Houghten RA, Plasterk RHA. A peptide inhibitor of HIV-1 integrase from a combinatorial library. Abstracts of the NIH Conference on Retroviral Integrase, Bethesda MD. 1995; January 19-20.
51. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-650.
52. Wai JS, Egbertson MS, Payne LS, Fisher TE, Embrey MW, Tran LO, et al. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem 2000; 43: 4923-4926.
53. Fesen M, Pommier Y, Leteurtre F, Hiroguchi S, Yung J, Kohn KW. Inhibition of HIV integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol 1994; 48: 595-608.
54. Neamati N, Mazumder A, Zhoa H, Sunder S, Burke TR Jr, Schultz RJ, et al. Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother 1997; 41: 385-393.
55. el Kouni MH. Trends in the design of nucleoside analogues as anti-HIV drugs. Curr Pharm Design 2002; 8(8): 581-93.
56. Jiang S, Zhao Q, Debnath AK. Peptide and non-peptide HIV fusion inhibitors. Curr Pharm Design 2002; 8(8): 563-80.
57. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, Litvak S. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches. Curr Pharm Design 2002; 8(8): 595-614.